Matowe W C, Ginsberg J
Department of Medicine, University of Alberta, Edmonton, Canada.
Pharmacology. 1996 Dec;53(6):376-83. doi: 10.1159/000139453.
We and others have demonstrated that protein kinase C (PKC) activators such as the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), inhibit differentiated thyroid function in vitro. However, phorbol-mediated PKC activation differs from that induced by analogues of the endogenous PKC activator, diacylglycerol (DAG). To explore the effects of endogenous PKC activation on differentiated thyroid function, we examined the effects of the DAG kinase inhibitor, R59022, on TSH-mediated iodide organification in porcine thyroid cells. Following incubation of the thyroid cells for 30 min, 20 and 50 mumol/l R59022 inhibited TSH-stimulated iodide organification by 20 and 41%, respectively. Prolonged exposure (36 h) to R59022 was also studied since similar treatment with TPA downregulates PKC activity. Inhibition of TSH-mediated iodide organification was observed with as little as 5 mumol/l R59022 (56% of control, p < 0.01) with maximal inhibition using 50 mumol/l R59022 to 13% of control values (p < 0.001). To demonstrate that these effects were mediated by PKC activation, PKC isoforms were measured by Western blotting following R59022 exposure (50 mumol/l, 30 min). Increased membrane-bound alpha- and zeta-PKC isozymes were observed. This is the first demonstration linking specific PKC isoforms to changes in differentiated thyroid function in vitro. The present data suggest that alpha- and/or zeta-PKC mediate the effects of R59022 on differentiated thyroid function in vitro. Further, a PKC inhibitor, chelerythrine (1 mumol/l) was able to partially reverse the effects of prolonged R59022 exposure on TSH-mediated iodide organification. These studies demonstrate that R59022 exposure inhibits TSH-mediated iodide organification in porcine thyroid cells and that these effects are mediated via endogenous PKC activation. These data are consistent with the concept that endogenous PKC acts as a negative modulator of differentiated thyroid function in the porcine thyroid cell.
我们及其他研究人员已证明,蛋白激酶C(PKC)激活剂,如佛波酯、12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA),在体外可抑制分化型甲状腺功能。然而,佛波醇介导的PKC激活与内源性PKC激活剂二酰基甘油(DAG)类似物诱导的激活不同。为探究内源性PKC激活对分化型甲状腺功能的影响,我们检测了DAG激酶抑制剂R59022对猪甲状腺细胞中促甲状腺激素(TSH)介导的碘有机化作用的影响。甲状腺细胞孵育30分钟后,20μmol/L和50μmol/L的R59022分别使TSH刺激的碘有机化作用降低了20%和41%。由于用TPA进行类似处理会下调PKC活性,因此我们还研究了长时间(36小时)暴露于R59022的情况。低至5μmol/L的R59022即可观察到对TSH介导的碘有机化作用的抑制(为对照值的56%,p < 0.01),使用50μmol/L的R59022时抑制作用最大,降至对照值的13%(p < 0.001)。为证明这些效应是由PKC激活介导的,在暴露于R59022(50μmol/L,30分钟)后,通过蛋白质印迹法检测PKC同工型。观察到膜结合的α - 和ζ - PKC同工酶增加。这是首次在体外将特定的PKC同工型与分化型甲状腺功能的变化联系起来。目前的数据表明,α - 和/或ζ - PKC介导了R59022对体外分化型甲状腺功能的影响。此外,一种PKC抑制剂白屈菜红碱(1μmol/L)能够部分逆转长时间暴露于R59022对TSH介导的碘有机化作用的影响。这些研究表明,暴露于R59022会抑制猪甲状腺细胞中TSH介导的碘有机化作用,且这些效应是通过内源性PKC激活介导的。这些数据与内源性PKC在猪甲状腺细胞中作为分化型甲状腺功能的负调节剂这一概念一致。